Clearstead Advisors, LLC Arcellx, Inc. Transaction History
Clearstead Advisors, LLC
- $6.44 Billion
- Q4 2024
A detailed history of Clearstead Advisors, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 33 shares of ACLX stock, worth $2,287. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33
Previous 54
38.89%
Holding current value
$2,287
Previous $4,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$303 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$260 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$244 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$241 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$231 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.04B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...